Mirati 2

Full Title: Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Details: This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation

Specialty: Oncology

Principal Investigator: Dr. Sylvia Blaskova

Study Status: Recruiting

Identifier: NCT04685135